These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 36714919)

  • 21. In-silico pharmacophoric and molecular docking-based drug discovery against the Main Protease (Mpro) of SARS-CoV-2, a causative agent COVID-19.
    Haider Z; Subhani MM; Farooq MA; Ishaq M; Khalid M; Akram MN; Khan RSA; Niazi AK
    Pak J Pharm Sci; 2020 Nov; 33(6):2697-2705. PubMed ID: 33867348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
    Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
    Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the SARS-CoV-2 main protease using FDA-approved Isavuconazonium, a P2-P3 α-ketoamide derivative and Pentagastrin: An in-silico drug discovery approach.
    Achilonu I; Iwuchukwu EA; Achilonu OJ; Fernandes MA; Sayed Y
    J Mol Graph Model; 2020 Dec; 101():107730. PubMed ID: 32920239
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.
    Guo S; Xie H; Lei Y; Liu B; Zhang L; Xu Y; Zuo Z
    Bioorg Chem; 2021 May; 110():104767. PubMed ID: 33667900
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of Diverse Natural Products as Inhibitors of SARS-CoV-2 M
    Rubio-Martínez J; Jiménez-Alesanco A; Ceballos-Laita L; Ortega-Alarcón D; Vega S; Calvo C; Benítez C; Abian O; Velázquez-Campoy A; Thomson TM; Granadino-Roldán JM; Gómez-Gutiérrez P; Pérez JJ
    J Chem Inf Model; 2021 Dec; 61(12):6094-6106. PubMed ID: 34806382
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Discovery of Small Allosteric and Active Site Inhibitors of the SARS-CoV-2 Main Protease via Structure-Based Virtual Screening and Biological Evaluation.
    Mahgoub RE; Mohamed FE; Alzyoud L; Ali BR; Ferreira J; Rabeh WM; AlNeyadi SS; Atatreh N; Ghattas MA
    Molecules; 2022 Oct; 27(19):. PubMed ID: 36235244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selection of SARS-CoV-2 main protease inhibitor using structure-based virtual screening.
    Hakami AR; Bakheit AH; Almehizia AA; Ghazwani MY
    Future Med Chem; 2022 Jan; 14(2):61-79. PubMed ID: 34814706
    [No Abstract]   [Full Text] [Related]  

  • 29. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M
    Soulère L; Barbier T; Queneau Y
    Comput Biol Chem; 2021 Jun; 92():107463. PubMed ID: 33677227
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of known drugs as potential SARS-CoV-2 Mpro inhibitors using ligand- and structure-based virtual screening.
    Federico LB; Silva GM; da Silva Hage-Melim LI; Gomes SQ; Barcelos MP; Galindo Francischini IA; Tomich de Paula da Silva CH
    Future Med Chem; 2021 Aug; 13(16):1353-1366. PubMed ID: 34169729
    [No Abstract]   [Full Text] [Related]  

  • 33. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery of novel SARS-CoV-2 inhibitors targeting the main protease M
    Mercorelli B; Desantis J; Celegato M; Bazzacco A; Siragusa L; Benedetti P; Eleuteri M; Croci F; Cruciani G; Goracci L; Loregian A
    Antiviral Res; 2022 Aug; 204():105350. PubMed ID: 35688349
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haste makes waste: A critical review of docking-based virtual screening in drug repurposing for SARS-CoV-2 main protease (M-pro) inhibition.
    Macip G; Garcia-Segura P; Mestres-Truyol J; Saldivar-Espinoza B; Ojeda-Montes MJ; Gimeno A; Cereto-Massagué A; Garcia-Vallvé S; Pujadas G
    Med Res Rev; 2022 Mar; 42(2):744-769. PubMed ID: 34697818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Virtual screening, ADMET prediction and dynamics simulation of potential compounds targeting the main protease of SARS-CoV-2.
    Yadav R; Imran M; Dhamija P; Chaurasia DK; Handu S
    J Biomol Struct Dyn; 2021 Oct; 39(17):6617-6632. PubMed ID: 32715956
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.
    Silvestrini L; Belhaj N; Comez L; Gerelli Y; Lauria A; Libera V; Mariani P; Marzullo P; Ortore MG; Palumbo Piccionello A; Petrillo C; Savini L; Paciaroni A; Spinozzi F
    Sci Rep; 2021 Apr; 11(1):9283. PubMed ID: 33927258
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery.
    Mahato S
    Med Chem; 2022; 18(8):847-858. PubMed ID: 35156586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Study of Drug Repurposing to Identify SARS-CoV-2 Main Protease (3CLpro) Inhibitors.
    Jo S; Signorile L; Kim S; Kim MS; Huertas O; Insa R; Reig N; Shin DH
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35742913
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phenylbenzopyrone of Flavonoids as a Potential Scaffold to Prevent SARSCoV-2 Replication by Inhibiting its M
    Potshangbam AM; Nongdam P; Kumar AK; Rathore RS
    Curr Pharm Biotechnol; 2021; 22(15):2054-2070. PubMed ID: 33504301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.